Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Safety, Efficacy of PBI-4050 & Its Effect on Relevant Biomarkers in T2DM Patients With Metabolic Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is 18 years of age or older.~2. Subject has signed written informed consent.~3. Subject has a clinical diagnosis of T2DM with an HbA1c level between ≥ 7.5% and ≤ 10%.~4. Subject has been receiving stable antidiabetic therapy (with or without basal insulin) for a minimum of 3 months before the screening visit.~5. Subject is able and willing to self-monitor blood glucose level at home.~6. Subject has a body mass index (BMI) of ≥ 27 kg/m2 and ≤ 45 kg/m2.~7. Subject has metabolic syndrome, having at least 3 of the 5 risk factors.~Exclusion Criteria:~1. Subject is using prandial insulin or pre-mixed insulin in addition to oral hypoglycaemic agents for blood glucose control.~2. Subject is taking basal insulin dose \> 1.0 U/kg/day.~3. Subject has recent or on-going infection requiring systemic treatment with an anti-infective agent within 30 days before screening.~4. Subject has a history of pancreatitis or diabetic ketoacidosis.~5. Subject has had at least one episode of severe hypoglycaemia in the past 12 months.~6. Subject has evidence of significant cardiovascular disease within 3 months before screening.~7. Subject has an estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m2.~8. Subject has uncontrolled hypertension.~9. Subject has a diagnosis of rheumatic or inflammatory disease; or other autoimmune or inflammatory disease.~10. Subject is concurrently taking and plans to routinely continue taking anti-inflammatory medications during the study.~11. Subject is currently using medications for the indication of (or at the doses indicated for) weight loss.~12. Subject has significantly elevated liver enzyme levels.~13. History of malignancy of any organ system, treated or untreated, within the past 5 years other than basal or squamous cell skin cancer.~14. Subject has a history of chronic alcohol or other substance abuse.~15. Subject has a history of an allergic reaction to PBI-4050 or any of its excipients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Daily dose of 6 capsules of placebo
- PBI-4050 400 mg (Type: ACTIVE_COMPARATOR): Daily dose of 2 capsules of PBI-4050 and 4 capsules of placebo
- PBI-4050 800 mg (Type: ACTIVE_COMPARATOR): Daily dose of 4 capsules of PBI-4050 and 2 capsules of placebo
- PBI-4050 1200 mg (Type: ACTIVE_COMPARATOR): Daily dose of 6 capsules of PBI-4050

Based on this trial design, predict the completion outcome and termination type (if applicable).